ホーム › がん（全種類） › ネブラスカ州 › Omaha
Omaha、NEにおけるがん（全種類）の臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、がん（全種類）に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
被験者募集中第3相
- University of Nebraska Medical Center, Omaha
- Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
被験者募集中第2/3相
- University Of Nebraska Medical Center, Omaha
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
被験者募集中第1相
- Nebraska Cancer Specialists, Omaha
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- 他8件
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
被験者募集中
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Fred and Pamela Buffett Cancer Center, Omaha
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Omaha
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Nebraska Medical Center, Omaha
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
被験者募集中観察研究
- Nebraska Cancer Specialists, Omaha
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
被験者募集中
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medicine, Omaha
- Nebraska Medicine - Bellevue, Bellevue · 9マイル先
他の都市におけるがん（全種類）の試験
- Houston, TX121件の研究
- New York City, NY110件の研究
- Boston, MA86件の研究
- Los Angeles, CA73件の研究
- Nashville, TN65件の研究
- Philadelphia, PA59件の研究
- Durham, NC58件の研究
- Washington, DC58件の研究
- Chicago, IL51件の研究
- Seattle, WA49件の研究
- Atlanta, GA49件の研究
- Arlington, VA48件の研究
Omahaにおける他の研究
- 前立腺がん27件の研究
- 非小細胞肺癌24件の研究
- 乳がん22件の研究
- 大腸癌18件の研究
- 多発性骨髄腫16件の研究
- 非ホジキンリンパ腫14件の研究
- 卵巣がん14件の研究
- 膵臓がん14件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 転移性癌13件の研究
- 腎臓がん（腎細胞がん）12件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。